API | naftopil

naftopil (Flivas) Report issue

Small molecule Experimental

AACT ChEMBL DrugBank Drug Central KEGG MeSH PubChem

Active Ingredient History

NOW

Now

Chemistry

SMILES: COc1ccccc1N1CCN(CC(O)COc2cccc3ccccc23)CC1
InChIKey: HRRBJVNMSRJFHQ-UHFFFAOYSA-N
Mol. Mass: 392.5
ALogP: 3.41 Partition coefficient
ChEMBL Molecules:

naftopidil

naftopidil dihydrochloride

More Chemistry

Pharmacology

Mechanisms of Action:
- Alpha-1A adrenergic receptor (Homo sapiens) ^UniProt
- Alpha-1D adrenergic receptor (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Oral
Pro Drug: No

1-(4-(2-methoxyphenyl)-1-piperazinyl)-3-(1-naphthyloxy)-2-propanol | avishot | flivas | naftopidil | naftopidil dihydrochloride | naftopidil hcl | naftopidil hydrochloride | naftopil

Organizations (15)

Research & Development (15)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (8)

Approved Indications (1)

Prostatic Hyperplasia

Experimental Indications - Clinical Trial Phases 1-4 (8)

Healthy Volunteers (Phase 1)

Hyperplasia (Phase 3)

Kidney Calculi (Phase 4)

Prostatic Hyperplasia ()

Prostatic Neoplasms (Phase 4)

Ureteral Diseases (Phase 4)

Urinary Tract Physiological Phenomena (Phase 4)

Urination Disorders (Phase 3)

Overview

Highest Phase: Phase 4
# of Trials: 7
# of Trial Organizations: 15

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue